Changes in Glycated Hemoglobin Levels after Introduction of Ambulatory Glucose Profile (AGP) Freestyle Libre Pro TM in Management of Type 2 Diabetes

Presentation Number: MON 639
Date of Presentation: April 3rd, 2017

Brijendra Kumar Srivastava*, Deepa M, Anjana Mohan and Mohan Viswanathan


Ambulatory Glucose Profile (AGP) FreeStyle Libre pro TM (Abbott) is a minimally invasive continuous glucose monitoring system (CGMS), which combines inputs from multiple days of CGM data and collates them into a single 24-hour period and is useful to study glycaemic variability. We hypothesized that the introduction of AGP in the management of type 2 diabetes would help in better glycemic control over and above standard treatment. We included the data from the diabetes electronic medical records of a tertiary care hospital for diabetes. Type 2 diabetic subjects from May 2015, who were initiated on AGP, were included in the study after excluding those with nephropathy (n = 462). Age and sex matched type 2 diabetic subjects who were on standard diabetes care in whom AGP was not used in, were included for comparison. The mean age of the diabetic subjects with and without AGP was 57.1 ± 10.2 vs. 56.8 ± 10.0 years; mean BMI 27.2 ± 4.0 vs. 27.2 ± 4.6 kg/m2; mean duration of diabetes 15.5 ± 8.1 vs. 13.9 ± 8.2 years and mean fasting glucose 172 ± 59 vs. 174 ± 58 mg/dl. After the introduction of AGP, the mean HbA1c dropped from 9.0 ± 1.4% to 7.9 ± 1.4% in the AGP group, whereas in the standard care group, the mean HbA1c dropped from 8.6 ± 1.4% to 8.1 ± 1.7%. Among the AGP group, the reduction in HbA1c was highest in those, who were in the third HbA1c tertile (2.22%) followed by those in the second HbA1c tertile (0.86%) and first HbA1c tertile (0.25%, p < 0.001). This ‘real life’ study provides evidence that use of AGP in type 2 diabetic subjects in a clinical setting may have an additional beneficial effect in lowering the HbA1c over and above the standard therapy.


Nothing to Disclose: BKS, DM, AM, MV